First Transgenic Cow With Cancer-fighting Proteins for Humans in China

by Rajashri on August 12, 2008 at 5:40 PM
 First Transgenic Cow With Cancer-fighting Proteins for Humans in China

A genetically altered cow that can produce cancer-fighting proteins for humans has been bred by Chinese researchers.

The cow, capable of producing CD20 antibodies in its milk, was born in Beijing on Aug. 2 and a dozen more are due to be born next month.


According to researchers, mass breeding of the animal would enable China to mass-produce the therapeutic proteins cheaply, reports Xinhua.

Lead author Li Ning, an academician with China Academy of Engineering, said that the human monoclonal (produced from a single cell) antibodies could be purified from the milk of the transgenic cow, and used to treat B cell lymphomas and leukemias and some auto-immune diseases.

"After 10 days of careful observation, we are happy to see the cow is very healthy," Li, whose laboratory is based in the China Agriculture University, said.

The weight of the calf at birth was 38 kg and in seven to eight months, the researchers would induce lactation to test its antibody expression.

The development is expected to significantly reduce the costs ofCD20 antibody production, which currently uses chimeric anti-CD20 CHO (Chinese hamster ovary) cells.

The low antibody expression level and high cost of cell culture has been a stumbling block in the industrial production of the antibody drug, which was approved by the U.S. Food and Drug Administration in 1997.

CD20 cell-surface proteins found in mature B cells become cancerous in patients who suffer from non-Hodgkins lymphoma, which accounts for about 40 percent of all new cases of lymphoma. It is identified as the target in the treatment of lymphomas.

"The objective of our research is to make the transgenic animal express the antibody at high levels," said Li.

Li added that transgenic mice had been able to express 10 mg/ml of CD20 antibody on average in tests.

The U.S.-based Business Communication Corp. has estimated the worldwide market for transgenically sourced therapies at more than1 billion U.S. dollars in 2008, and 18.6 billion dollars by 2013.

Researchers planned to complete the clinical study of the first functional food with the antibody in three years, and apply for production authorization from China's food and drug authorities, and the first functional drug could be expected in five years.

Source: ANI
Font : A-A+



Recommended Readings

Latest Research News

South Korea's 2050 Forecast: Negative Growth Amid Low Fertility
South Korea's total fertility rate, averaging the number of children a woman aged 15-49 has in her lifetime, dropped to 0.81.
New Immunotherapy for Psoriasis & Vitiligo
Scientists identified mechanisms governing immune cells, selectively removing troublemakers to reshape skin immunity. Benefits those with psoriasis, vitiligo.
2050 Forecast: 1.06 Billion Individuals to Face 'Other' Musculoskeletal Disorders
By 2050, an anticipated increase from 494 million cases in 2020 to 1.06 billion people with musculoskeletal disabilities is expected.
Gene Therapies Can Disrupt Gaucher Disease Drug Market
Experts consulted by GlobalData anticipate a significant overhaul in the Gaucher disease scenario because of forthcoming gene therapies in development.
NASH Cases Expected to Hit 26.55 Million in 7MM by 2032
Within the seven major markets, 12% to 20% of diagnosed prevalent NASH cases present severe liver damage (stage 4 liver fibrosis), denoting cirrhosis.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

First Transgenic Cow With Cancer-fighting Proteins for Humans in China Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests